Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?

Shyamkumar, Krishnan; Hirsh, Jack; Bhagirath, Vinai C; Sinha, Smita; Xu, Ke; Ginsberg, Jeffrey S; Díaz, Rafael; Eikelboom, John W; Chan, Noel C

Shyamkumar, Krishnan; Hirsh, Jack; Bhagirath, Vinai C; Sinha, Smita; Xu, Ke; Ginsberg, Jeffrey S; Díaz, Rafael; Eikelboom, John W; Chan, Noel C.

Afiliação

Shyamkumar K; Population Health Research Institute, Hamilton, ON L8L 2X2, Canada.
Hirsh J; Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
Bhagirath VC; Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
Sinha S; Thrombosis & Atherosclerosis Research Institute, Hamilton, ON L8L 2X2, Canada.
Xu K; Population Health Research Institute, Hamilton, ON L8L 2X2, Canada.
Ginsberg JS; University Hospitals Birmingham, Birmingham, UK.
Díaz R; Population Health Research Institute, Hamilton, ON L8L 2X2, Canada.
Eikelboom JW; Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Chan NC; Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.

Future Cardiol ; 17(1): 175-182, 2021 01.

Article em En | MEDLINE | ID: mdl-32559114

Assuntos

Aterosclerose; Rivaroxabana; Aspirina/uso terapêutico; Aterosclerose/tratamento farmacológico; Quimioterapia Combinada; Fibrinolíticos/uso terapêutico; Humanos; Inibidores da Agregação Plaquetária/uso terapêutico

Palavras-chave

anticoagulant; antiplatelet therapy; antithrombotic therapy; aspirin; atherosclerosis; low-dose rivaroxaban; mortality; myocardial infarction; stroke

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aterosclerose / Rivaroxabana Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google